Annexon ANNX
NASDAQ ANNX
$4.87 +0.03 (+0.62%)
As of: Sep 4, 2026 · 3:59 PM EDT

Annexon (ANNX) Liabilities and Shareholders Equity (2019 - 2026)

Annexon (ANNX) posted quarterly Liabilities and Shareholders Equity of $262.9 million for Q1 2026, down 13.25% year-over-year from $303.0 million in Q1 2025, and down 5.29% quarter-over-quarter from $277.6 million in Q4 2025.

Analysis

Annexon (ANNX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Annexon's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $262.9 million for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity fell 13.25% year-over-year to $262.9 million; the TTM figure through Mar 2026 stood at $1.0 billion (down 28.08% YoY), while the FY2025 annual figure was $277.6 million, down 20.71% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $262.9 million, down from $277.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $406.1 million in Q2 2024, with the low at $203.8 million in Q3 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $277.6 million (2025), against an average of $285.2 million.
  • The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity jumped 85.84% in 2024, then sank 39.5% in 2025.
  • Annexon's Liabilities and Shareholders Equity stood at $285.1 million in 2022, then grew by 4.41% to $297.7 million in 2023, then climbed by 17.6% to $350.1 million in 2024, then decreased by 20.71% to $277.6 million in 2025, then decreased by 5.29% to $262.9 million in 2026.
  • Business Quant data shows ANNX's Liabilities and Shareholders Equity at $262.9 million in Q1 2026, $277.6 million in Q4 2025, and $229.1 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Annexon 982.93 Mn 982.93 Mn - 246.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 246.07 Mn
Mar 31, 2026 262.89 Mn
Dec 31, 2025 277.57 Mn
Sep 30, 2025 229.14 Mn
Jun 30, 2025 264.57 Mn
Mar 31, 2025 303.03 Mn
Dec 31, 2024 350.07 Mn
Sep 30, 2024 378.78 Mn
Jun 30, 2024 406.09 Mn
Mar 31, 2024 304.07 Mn
Dec 31, 2023 297.67 Mn
Sep 30, 2023 203.82 Mn
Jun 30, 2023 233.01 Mn
Mar 31, 2023 268.78 Mn
Dec 31, 2022 285.10 Mn
Sep 30, 2022 312.72 Mn
Jun 30, 2022 220.70 Mn
Mar 31, 2022 250.57 Mn
Dec 31, 2021 287.04 Mn
Sep 30, 2021 310.16 Mn